(VIANEWS) – Universal Display Corporation (OLED), Selective Insurance Group (SIGI), AAON (AAON) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Universal Display Corporation (OLED)
20.2% sales growth and 14.91% return on equity
Universal Display Corporation engages in the research, development, and commercialization of organic light emitting diode (OLED) technologies and materials for use in display and solid-state lighting applications. It owns, exclusively licenses, or has sole rights to sublicense approximately 5,500 issued and pending patents worldwide. The company supplies its proprietary UniversalPHOLED materials to display and lighting manufacturers, and others. It is also involved in the research, development, and commercialization of other OLED device and manufacturing technologies, including FOLED that are flexible OLEDs for the fabrication of OLEDs on flexible substrates; OVJP, an organic vapor jet printing technology; thin-film encapsulation technology for the packaging of flexible OLEDs and other thin-film devices, as well as for use as a barrier film for plastic substrates; and UniversalP2OLED, which are printable phosphorescent OLEDs. In addition, the company provides technology development and support services, including third-party collaboration and support to third parties for the commercialization of their OLED products. Further, it provides contract research services in the areas of chemical materials synthesis research, development, and commercialization for non-OLED applications. Universal Display Corporation was founded in 1985 and is headquartered in Ewing, New Jersey.
Earnings Per Share
As for profitability, Universal Display Corporation has a trailing twelve months EPS of $4.24.
PE Ratio
Universal Display Corporation has a trailing twelve months price to earnings ratio of 39.13. Meaning, the purchaser of the share is investing $39.13 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.91%.
Volume
Today’s last reported volume for Universal Display Corporation is 63555 which is 78.38% below its average volume of 293965.
2. Selective Insurance Group (SIGI)
11.7% sales growth and 13.32% return on equity
Selective Insurance Group, Inc., together with its subsidiaries, provides insurance products and services in the United States. It operates through four segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, and Investments. The company offers property insurance products, which covers the financial consequences of accidental loss of an insured's real property, personal property, and/or earnings due to the property's loss; and casualty insurance products that covers the financial consequences of employee injuries in the course of employment, and bodily injury and/or property damage to a third party, as well as flood insurance products. It also invests in fixed income investments and commercial mortgage loans, as well as equity securities and alternative investment portfolio. The company offers its insurance products and services to businesses, non-profit organizations, local government agencies, and individuals through independent retail agents and wholesale general agents. Selective Insurance Group, Inc. was founded in 1926 and is headquartered in Branchville, New Jersey.
Earnings Per Share
As for profitability, Selective Insurance Group has a trailing twelve months EPS of $5.84.
PE Ratio
Selective Insurance Group has a trailing twelve months price to earnings ratio of 18.04. Meaning, the purchaser of the share is investing $18.04 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.32%.
Yearly Top and Bottom Value
Selective Insurance Group’s stock is valued at $105.38 at 20:22 EST, under its 52-week high of $108.18 and way above its 52-week low of $91.93.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.6%, now sitting on 4.23B for the twelve trailing months.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Feb 14, 2024, the estimated forward annual dividend rate is 1.3 and the estimated forward annual dividend yield is 1.25%.
Sales Growth
Selective Insurance Group’s sales growth is 15% for the ongoing quarter and 11.7% for the next.
3. AAON (AAON)
10.5% sales growth and 27.41% return on equity
AAON, Inc., together with its subsidiaries, engages in engineering, manufacturing, marketing, and selling air conditioning and heating equipment in the United States and Canada. The company operates through three segments: AAON Oklahoma, AAON Coil Products, and BASX. It offers rooftop units, data center cooling solutions, cleanroom systems, chillers, packaged outdoor mechanical rooms, air handling units, makeup air units, energy recovery units, condensing units, geothermal/water-source heat pumps, coils, and controls. The company markets and sells its products to retail, manufacturing, educational, lodging, supermarket, data centers, medical and pharmaceutical, and other commercial industries. It sells its products through a network of independent manufacturer representative organizations and internal sales force, as well as online. The company was incorporated in 1987 and is based in Tulsa, Oklahoma.
Earnings Per Share
As for profitability, AAON has a trailing twelve months EPS of $2.13.
PE Ratio
AAON has a trailing twelve months price to earnings ratio of 40.84. Meaning, the purchaser of the share is investing $40.84 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.41%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Mar 15, 2024, the estimated forward annual dividend rate is 0.32 and the estimated forward annual dividend yield is 0.38%.
Sales Growth
AAON’s sales growth is 7.1% for the ongoing quarter and 10.5% for the next.
4. Copart (CPRT)
7.2% sales growth and 22.55% return on equity
Copart, Inc. provides online auctions and vehicle remarketing services in the United States, Canada, the United Kingdom, Brazil, the Republic of Ireland, Germany, Finland, the United Arab Emirates, Oman, Bahrain, and Spain. It offers a range of services for processing and selling vehicles over the internet through its virtual bidding third generation internet auction-style sales technology to vehicle sellers, insurance companies, banks and finance companies, charities, fleet operators, dealers, vehicle rental companies, and individuals. The company's services include online seller access, salvage estimation, estimating, end-of-life vehicle processing, transportation, vehicle inspection stations, on-demand reporting, title processing and procurement, loan payoff, flexible vehicle processing programs, buy it now, member network, sales process, and dealer services. Its services also comprise services to sell vehicles through CashForCars.com, CashForCars.ca, CashForCars.de, CashForCars.co.uk, and Cash-for-cars.ie; Copart Recycling service, which allows the public to purchase parts from salvaged and end-of-life vehicles; copart 360, an online technology for posting vehicle images that captures clear 360-degree views of interiors and exteriors of cars, trucks, and vans; membership tiers for those registering to buy vehicles through Copart.com; and virtual queue to secure a place in line while visiting one of its locations. In addition, it provides non-salvage powersport vehicle remarketing services through live and online auction platforms. The company sells its products principally to licensed vehicle dismantlers, rebuilders, repair licensees, used vehicle dealers, and exporters, as well as to the public. Copart, Inc. was incorporated in 1982 and is headquartered in Dallas, Texas.
Earnings Per Share
As for profitability, Copart has a trailing twelve months EPS of $1.4.
PE Ratio
Copart has a trailing twelve months price to earnings ratio of 40.98. Meaning, the purchaser of the share is investing $40.98 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.55%.
Moving Average
Copart’s value is way higher than its 50-day moving average of $49.83 and way higher than its 200-day moving average of $46.54.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.6%, now sitting on 4.06B for the twelve trailing months.
Yearly Top and Bottom Value
Copart’s stock is valued at $57.37 at 20:22 EST, above its 52-week high of $55.83.
Previous days news about Copart(CPRT)
- Is it worth investing in copart (cprt) based on wall street's bullish views?. According to Zacks on Monday, 1 April, "Check price target & stock forecast for Copart here>>>While the ABR calls for buying Copart, it may not be wise to make an investment decision solely based on this information. ", "Therefore, it could be wise to take the Buy-equivalent ABR for Copart with a grain of salt."
5. Bank OZK (OZK)
7.2% sales growth and 14.05% return on equity
Bank OZK provides various retail and commercial banking services. The company accepts various deposit products, including non-interest-bearing checking, interest bearing transaction, business sweep, savings, money market, individual retirement, and other accounts, as well as time deposits. It also offers real estate, consumer and business purpose, indirect recreational vehicle and marine, commercial and industrial, government guaranteed, agricultural equipment, small business, lines of credit, homebuilder, and affordable housing loans; business aviation and subscription financing services; and mortgage and other lending products. In addition, the company provides trust and wealth services, such as personal trusts, custodial accounts, investment management accounts, and retirement accounts, as well as corporate trust services, including trustee, paying agent and registered transfer agent services, and other related services. Further, it offers treasury management services comprising automated clearing house, wire transfer, transaction reporting, wholesale lockbox, remote deposit capture, automated credit line transfer, reconciliation, positive pay, merchant and commercial card, and other services, as well as zero balance and investment sweep accounts. Additionally, the company provides ATMs; telephone, online, and mobile banking services; debit and credit cards; safe deposit boxes; and other products and services, as well as processes merchant debit and credit card transactions. The company was formerly known as Bank of the Ozarks and changed its name to Bank OZK in July 2018. Bank OZK was founded in 1903 and is headquartered in Little Rock, Arkansas.
Earnings Per Share
As for profitability, Bank OZK has a trailing twelve months EPS of $5.87.
PE Ratio
Bank OZK has a trailing twelve months price to earnings ratio of 7.74. Meaning, the purchaser of the share is investing $7.74 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.05%.
Sales Growth
Bank OZK’s sales growth is 12.5% for the ongoing quarter and 7.2% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 4.3% and a drop 0.7% for the next.
6. Jazz Pharmaceuticals plc (JAZZ)
6.7% sales growth and 12.16% return on equity
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, Jazz Pharmaceuticals plc has a trailing twelve months EPS of $6.1.
PE Ratio
Jazz Pharmaceuticals plc has a trailing twelve months price to earnings ratio of 19.97. Meaning, the purchaser of the share is investing $19.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.16%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.1%, now sitting on 3.83B for the twelve trailing months.
Volume
Today’s last reported volume for Jazz Pharmaceuticals plc is 691817 which is 11.56% above its average volume of 620090.
Sales Growth
Jazz Pharmaceuticals plc’s sales growth is 7.1% for the present quarter and 6.7% for the next.
